Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
Johnson and Johnson
Moodys
Cipla
Chubb
QuintilesIMS
Julphar
Dow
UBS

Generated: May 26, 2018

DrugPatentWatch Database Preview

Claims for Patent: 7,605,240

« Back to Dashboard

Summary for Patent: 7,605,240
Title:Methods of treating diarrhea and bloating caused by small intestinal bacterial overgrowth
Abstract: Disclosed is a method of diagnosing irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, such as multiple sclerosis and systemic lupus erythematosus, or Crohn's disease, which involves detecting the presence of small intestinal bacterial overgrowth (SIBO) in a human subject having at least one symptom associated with a suspected diagnosis of any of those diagnostic categories. Also disclosed is a method of treating these disorders, and other disorders caused by SIBO, that involves at least partially eradicating a SIBO condition in the human subject. The method includes administration of anti-microbial or probiotic agents, or normalizing intestinal motility by employing a prokinetic agent. The method improves symptoms, including hyperalgesia related to SIBO and disorders caused by SIBO. Also disclosed is a kit for the diagnosis or treatment of irritable bowel syndrome, fibromyalgia, chronic fatigue syndrome, depression, attention deficit/hyperactivity disorder, autoimmune diseases, or Crohn's disease.
Inventor(s): Lin; Henry C. (Albuquerque, NM), Pimentel; Mark (Los Angeles, CA)
Assignee: Cedara-Sinai Medical Center (Los Angeles, CA)
Application Number:11/838,672
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,605,240
Patent Claims: 1. A method of treating bloating in a subject, comprising: providing a composition comprising rifaximin; and administering the composition to the subject in an amount sufficient to at least partially eradicate small intestinal bacterial overgrowth in the subject, wherein the subject has small intestinal bacterial overgrowth and whereby the bloating is treated.

2. The method of claim 1, wherein the rifaximin is administered orally.

3. The method of claim 1, wherein the composition comprises a unitized amount of rifaximin.

4. The method of claim 1, wherein the rifaximin is dehydrated rifaximin.

5. The method of claim 1, where in the rifaximin is lyophilized rifaximin.

6. The method of claim 1, wherein the administering results in complete eradication of the small intestinal bacterial overgrowth.

7. The method of claim 1, wherein the administering results in greater than 90% improvement in bloating.

8. A method of treating bloating in a subject suffering from small intestinal bacterial overgrowth, comprising administering rifaximin to the subject in an amount sufficient to at least partially eradicate the small intestinal bacterial overgrowth.

9. The method of claim 8, wherein the rifaximin is administered orally.

10. The method of claim 8, wherein the composition comprises a unitized amount of rifaximin.

11. The method of claim 8, wherein the rifaximin is dehydrated rifaximin.

12. The method of claim 8, where in the rifaximin is lyophilized rifaximin.

13. The method of claim 8, wherein the administering results in complete eradication of the small intestinal bacterial overgrowth.

14. The method of claim 8, wherein the administering results in greater than 90% improvement in bloating.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Cantor Fitzgerald
Queensland Health
Julphar
Boehringer Ingelheim
Johnson and Johnson
US Department of Justice
Express Scripts
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.